Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?

Pharmacological Research

Volumn 62, Issue 5, 2010, Pages 365-383

  Balakumar, Pitchai ^a   Jagadeesh, Gowraganahalli ^b  

^a SB College of Pharmacy   (India)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cardiac hypertrophy; Genetic alterations; Heart failure; Pharmacological interventions; Signaling mechanisms; Transcription factors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CALCINEURIN; CARIPORIDE; CASPASE 3; CROCETIN; EPIGALLOCATECHIN GALLATE; ETANERCEPT; FASUDIL; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; INTEGRIN; ISTAROXIME; JANUS KINASE; KALLIKREIN; LEVOSIMENDAN; MITOFUSIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NEOSTIGMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PILOCARPINE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RESVERATROL; RHO KINASE; TETRANDRINE; TRANSCRIPTION FACTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TUMOR NECROSIS FACTOR ALPHA; TYRPHOSTIN; UNINDEXED DRUG; WNT PROTEIN;

CARDIOVASCULAR DISEASE; CELL SIZE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; MAMMAL; MECHANICAL STRESS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ADENOSINE DIPHOSPHATE RIBOSE; ANIMALS; CALCINEURIN; CARDIOMEGALY; FEMALE; HEART FAILURE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956918119     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.07.003     Document Type: Review

References (302)

1. Carreno J.E., Apablaza F., Ocaranza M.P., Jalil J.E. Cardiac hypertrophy: molecular and cellular events. Rev Esp Cardiol 2006, 59:473-486.
2. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Ann Rev Physiol 2003, 65:45-79.
3. Balakumar P., Singh A.P., Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 2007, 56:1-10.
4. Balakumar P., Singh H., Singh M., Anand-Srivastava M.B. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res 2009, 60:18-23.
5. Chien K.R. Stress pathways and heart failure. Cell 1999, 98:555-558.
6. Hilfiker-Kleiner D., Landmesser U., Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006, 48:A56-66.
7. Beisvag V., Kemi O.J., Arbo I., Loennechen J.P., Wisløff U., Langaas M., et al. Pathological and physiological hypertrophies are regulated by distinct gene programs. Eur J Cardiovasc Prev Rehabil 2009, 16:690-697.
8. Usui S., Yeh I., Tian B., Sadoshima J. Global changes in gene expression during cardiac hypertrophy: a new direction of cardiac signaling research. J Mol Cell Cardiol 2006, 41:219-222.
9. Van den Bosch B.J.C., Lindsey P.J., van den Burg C.M.M., van der Vlies S.A., Lips D.J., van der Vusse G.J., et al. Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics 2006, 88:480-488.
10. Tan F.L., Moravec C.S., Li J., Apperson-Hansen C., McCarthy P.M., Young J.B., et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci USA 2002, 99:11387-11392.
11. Houser S.R., Margulies K.B. Is depressed myocyte contractility centrally involved in heart failure?. Circ Res 2003, 92:350-358.
12. + exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol 2000, 278:H300-H304.
13. Terracciano C. Functional consequences of Na/Ca exchanger overexpression in cardiac myocytes. Ann N Y Acad Sci 2002, 976:520-527.
14. Gan X.T., Gong X.Q., Xue J., Haist J.V., Bai D., Karmazyn M. Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes. Cardiovasc Res 2010, 85:79-89.
15. Garciarena C.D., Caldiz C.I., Portiansky E.L., Chiappe de Cingolani G.E., Ennis I.L. Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart. J Appl Physiol 2009, 106:1325-1331.
16. Blum A., Miller H. Role of cytokines in heart failure. Am Heart J 1998, 135:181-186.
17. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994, 105:897-904.
18. Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470.
19. Balakumar P., Singh M. Anti-TNF-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006, 99:391-397.
20. Henriksen P.A., Newby D.E. Therapeutic inhibition of tumor necrosis factor (in patients with heart failure: cooling an inflamed heart. Heart 2003, 89:14-18.
21. Cairns C.B., Panacek E.A., Harken A.H., Banerjee A. Bench to bedside: tumor necrosis factor-alpha: from inflammation to resuscitation. Acad Emerg Med 2000, 7:930-941.
22. Nakano M., Knowlton A.A., Dibbs Z., Mann D.L. Tumor necrosis factor-α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998, 97:1392-1400.
23. Kurrelmeyer K.M., Michael L.H., Baumgarten G., Taffet G.E., Peschon J.J., Sivasubramanian N., et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000, 97:5456-5461.
24. Sarzi-Puttini P., Atzeni F., Doria A., Iaccarino L., Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005, 14:780-784.
25. Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J.E. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for the in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996, 183:949-958.
26. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 1998, 274:R577-R595.
27. Torre-Amione G., Vooletich M., Farmer J. Role of tumor necrosis factor-alpha in the progression of heart failure. Therapeutic implications. Drugs 2000, 59:745-751.
28. Das S., Babick A.P., Xu Y.J., Takeda N., Rodriguez-Levya D., Dhalla N.S. TNF-alpha mediated signal transduction pathway is a major determinant of apoptosis in dilated cardiomyopathy. J Cell Mol Med 2009, 10.1111/j.1582-4934.2009.00904.x.
29. Meijs M.F.L., de Windt L.J., de Jonge N., Cramer M.J.M., Bots M.L., Mali W.P.T.M., et al. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 2007, 14:157-171.
30. Sriramula S., Haque M., Majid D.S., Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008, 51:1345-1351.
31. Freeling J., Wattier K., LaCroix C., Li Y.F. Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. Exp Physiol 2008, 93:75-82.
32. Jobe L.J., Meléndez G.C., Levick S.P., Du Y., Brower G.L., Janicki J.S. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009, 297:H1462-H1468.
33. Yndestad A. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002, 54:175-182.
34. Yndestad A. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003, 60:141-146.
35. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
36. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S.S., et al. Disregulated osteopotegrin/RANK-ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468.
37. Walsh M. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003, 14:251-263.
38. Bogaty P., Brophy J.M., Boyer L., Simard S., Joseph L., Bertrand F., et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005, 165:221-226.
39. Campbell D.J., Woodward M., Chalmers J.P., Colman S.A., Jenkins A.J., Kemp B.E., et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 2005, 45:69-74.
40. Satoh M., Nakamura M., Akatsu T., Shimoda Y., Segawa I., Hiramori K. C-reactive protein co-expresses with tumor necrosis factor-α in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 2005, 7:748-754.
41. van de Schans V.A., Smits J.F., Blankesteijn W.M. The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe?. Eur J Pharmacol 2008, 585:338-345.
42. van de Schans V.A., van den Borne S.W., Strzelecka A.E., Janssen B.J., van der Velden J.L., Langen R.C., et al. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 2007, 49:473-480.
43. Blankesteijn W.M., van de Schans V.A., ter Horst P., Smits J.F. The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci 2008, 29:175-180.
44. Baurand A., Zelarayan L., Betney R., Gehrke C., Dunger S., Noack C., et al. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ Res 2007, 100:1353-1362.
45. Zhang C.G., Jia Z.Q., Li B.H., Zhang H., Liu Y.N., Chen P., et al. beta-catenin/TCF/LEF1 can directly regulate phenylephrine-induced cell hypertrophy and Anf transcription in cardiomyocytes. Biochem Biophys Res Commun 2009, 390:258-262.
46. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Ann Rev Physiol 1997, 59:551-571.
47. Manso A.M., Kang S.M., Ross R.S. Integrins, focal adhesions, and cardiac fibroblasts. J Investig Med 2009, 57:856-860.
48. Huveneers S., Danen E.H. Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci 2009, 122:1059-1069.
49. Brancaccio M., Hirsch E., Notte A., Selvetella G., Lembo G., Tarone G. Integrin signalling: the tug-of-war in heart hypertrophy. Cardiovasc Res 2006, 70:422-433.
50. Lal H., Verma S.K., Foster D.M., Golden H.B., Reneau J.C., Watson L.E., et al. Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci 2009, 14:2307-2334.
51. Krishnamurthy P., Subramanian V., Singh M., Singh K. Beta1 integrins modulate beta-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling. Hypertension 2007, 49:865-872.
52. Brancaccio M., Fratta L., Notte A., Hirsch E., Poulet R., Guazzone S., et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 2003, 9:68-75.
53. De Acetis M., Notte A., Accornero F., Selvetella G., Brancaccio M., Vecchione C., et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ Res 2005, 96:1087-1094.
54. 3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J 2009, 23:2759-2771.
55. Sharma J.N. Cardiovascular activities of the bradykinin system. Sci World J 2008, 8:384-393.
56. Silva J.A., Araujo R.C., Baltatu O., Oliveira S.M., Tschope C., Fink E., et al. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 2000, 14:1858-1860.
57. Bledsoe G., Chao L., Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003, 285:H1479-H1488.
58. Li H.J., Yin H., Yao Y.Y., Shen B., Bader M., Chao L., et al. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3β activation. Cardiovasc Res 2007, 73:130-142.
59. Yao Y.Y., Yin H., Shen B., Chao L., Chao J. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail 2007, 13:588-596.
60. Pons S., Griol-Charhbili V., Heymes C., Fornes P., Heudes D., Hagege A., et al. Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur J Heart Fail 2008, 10:343-351.
61. Seth M., Zhang Z.S., Mao L., Graham V., Burch J., Stiber J., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ Res 2009, 105:1023-1030.
62. Nishida M., Sato Y., Nakaya M., Kurose H. Regulation of cardiac hypertrophy by the formation of G protein-coupled receptor-TRPC channel protein complex. Nippon Yakurigaku Zasshi 2009, 134:131-136.
63. Molkentin J.D., Dorn G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Ann Rev Physiol 2001, 63:391-426.
64. Vega R.B., Bassel-Duby R., Olson E.N. Control of cardiac growth and function by calcineurin signaling. J Biol Chem 2003, 278:36981-36984.
65. Ito H., Hirata Y., Adachi S., Tanaka M., Tsujino M., Koike A., et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993, 92:398-403.
66. Hunton D.L., Lucchesi P.A., Pang Y., Cheng X., Dell'Italia L.J., Marchase R.B. Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem 2002, 277:14266-14273.
67. Parekh A.B., Putney J.W. Store-operated calcium channels. Physiol Rev 2005, 85:757-810.
68. Huang G.N., Zeng W., Kim J.Y., Yuan J.P., Han L., Muallem S., et al. STIM1 carboxyl-terminus activates native SOC, I(crac) and TRPC1 channels. Nat Cell Biol 2006, 8:1003-1010.
69. Ohba T., Watanabe H., Murakami M., Takahashi Y., Ito H. Increased expression of transient receptor potential c1 in rats with hypertensive hypertrophy. Akita J Med 2006, 32:45-51.
70. Ohba T., Watanabe H., Murakami M., Takahashi Y., Iino K., Kuromitsu S., et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol 2007, 42:498-507.
71. Reddy R.N., Knotts T.L., Roberts B.R., Molkentin J.D., Price S.R., Gooch J.L. Calcineurin A-beta is required for hypertrophy but not matrix expansion in the diabetic kidney. J Cell Mol Med 2009, 10.1111/j.1582-4934.2009.00910.x.
72. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
73. Luedde M., Katus H.A., Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Patent Cardiovasc Drug Discov 2006, 1:1-20.
74. Bourajjaj M., Armand A.S., da Costa Martins P.A., Weijts B., van der Nagel R., Heeneman S., et al. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008, 283:22295-22303.
75. Taigen T., De Windt L.J., Lim H.W., Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000, 97:1196-1201.
76. Abrenica B., AlShaaban M., Czubryt M.P. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J Mol Cell Cardiol 2009, 46:674-681.
77. Kuhn C., Frank D., Will R., Jaschinski C., Frauen R., Katus H.A., et al. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem 2009, 284:17320-17327.
78. Kingsbury T.J., Cunningham K.W. A conserved family of calcineurin regulators. Genes Dev 2000, 14:1595-1604.
79. Hill J.A., Rothermel B., Yoo K.D., Cabuay B., Demetroulis E., Weiss R.M., et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 2002, 277:10251-10255.
80. Frey N., Barrientos T., Shelton J.M., Frank D., Rutten H., Gehring D., et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004, 10:1336-1343.
81. Cha H., Kim J.M., Oh J.G., Jeong M.H., Park C.S., Park J., et al. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol 2008, 45:796-803.
82. Li J., Negro A., Lopez J., Bauman A.L., Henson E., Dodge-Kafka K., et al. The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol 2010, 48:387-394.
83. Meyer-Kirchrath J., Martin M., Schooss C., Jacoby C., Flögel U., Marzoll A., et al. Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart. Cardiovasc Res 2009, 81:310-318.
84. Sheng H., Zhu J., Wu X., Zhang J. Blockade of calcineurin reverses cardiac hypertrophy and induces the down-regulation of JNK mRNA expression in renovascular hypertensive rats. J Renin Angiotensin Aldosterone Syst 2008, 9:139-145.
85. Gelpi R.J., Gao S., Zhai P., Yan L., Hong C., Danridge L.M., et al. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload. Am J Physiol Heart Circ Physiol 2009, 297:H1814-H18149.
86. Somers J.R., Beck P.L., Lees-Miller J.P., Roach D., Li Y., Guo J., et al. iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. Am J Physiol Heart Circ Physiol 2008, 295:H1122-H1131.
87. Bach D., Pich S., Soriano F.X., Vega N., Baumgartner B., Oriola J., et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 2003, 278:17190-17197.
88. Chen H., Detmer S.A., Ewald A.J., Griffin E.E., Fraser S.E., Chan D.C. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003, 160:189-200.
89. Fang L., Moore X.L., Gao X.M., Dart A.M., Lim Y.L., Du X.J. Down-regulation of mitofusin-2 expression in cardiac hypertrophy in vitro and in vivo. Life Sci 2007, 80:2154-2160.
90. Chen C.L., Shen T., Zheng M., Guo Y.H., Zhu X.J., Chen G.H. Inhibition of cardiac hypertrophy by mitofusin 2 in neonatal rat cardiomyocytes. Beijing Da Xue Xue Bao 2008, 40:528-532.
91. Li Y., Yin R., Liu J., Wang P., Wu S., Luo J., et al. Peroxisome proliferator-activated receptor delta regulates mitofusin 2 expression in the heart. J Mol Cell Cardiol 2009, 46:876-882.
92. Bueno O.F., De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001, 88:88-96.
93. Lorenz K., Schmitt J.P., Vidal M., Lohse M.J. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol 2009, 41:2351-2355.
94. Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009, 15:75-83.
95. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. β-Arrestins and cell signaling. Ann Rev Physiol 2007, 69:483-510.
96. Samarel A.M. Costameres, focal adhesions, and cardiomyocyte mechanotransduction. Am J Physiol Heart Circ Physiol 2005, 289:H2291-H2301.
97. Yund E.E., Hill J.A., Keller R.S. Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes. J Mol Cell Cardiol 2009, 47:520-527.
98. Clerk A., Sugden P.H. Untangling the web: specific signaling from PKC isoforms to MAPK cascades. Circ Res 2001, 89:847-849.
99. Heidkamp M.C., Bayer A.L., Martin J.L., Samarel A.M. Differential activation of mitogen-activated protein kinase cascades and apoptosis by protein kinase C epsilon and delta in neonatal rat ventricular myocytes. Circ Res 2001, 89:882-890.
100. Strait J.B., Martin J.L., Bayer A., Mestril R., Eble D.M., Samarel A.M. Role of protein kinase C-epsilon in hypertrophy of cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2001, 280:H756-H766.
101. Jagadeesh G. Angiotensin II receptors: antagonists, molecular biology, and signal transduction. Ind J Exp Biol 1998, 36:1171-1194.
102. Paul A., Wilson S., Belham C.M., Robinson C.J., Scott P.H., Gould G.W., et al. Stress-activated protein kinases: activation, regulation and function. Cell Signal 1997, 9:403-410.
103. 2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophy. Cell Biochem Biophys 2005, 43:61-76.
104. Lei B., Chess D.J., Keung W., O'Shea K.M., Lopaschuk G.D., Stanley W.C. Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008, 45:404-410.
105. Kompa A.R., See F., Lewis D.A., Adrahtas A., Cantwell D.M., Wang B.H., et al. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther 2008, 325:741-750.
106. Wang Y., Huang S., Sah V.P., Ross J., Brown J.H., Han J., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998, 273:2161-2168.
107. Zou X.J., Yang L., Yao S.L. Propofol depresses angiotensin II-induced cardiomyocyte hypertrophy in vitro. Exp Biol Med (Maywood) 2008, 233:200-208.
108. Lu Y.M., Shioda N., Han F., Kamata A., Shirasaki Y., Qin Z.H., et al. DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities. Cardiovasc Ther 2009, 27:17-27.
109. Willette R.N., Eybye M.E., Olzinski A.R., Behm D.J., Aiyar N., Maniscalco K., et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther 2009, 330:964-970.
110. Deng J., Lv X.T., Wu Q., Huang X.N. Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings. Eur J Pharmacol 2009, 608:42-47.
111. Chen D.D., Dong Y.G., Liu D., He J.G. Epigallocatechin-3-gallate attenuates cardiac hypertrophy in hypertensive rats in part by modulation of mitogen-activated protein kinase signals. Clin Exp Pharmacol Physiol 2009, 36:925-932.
112. Hebenstreit D., Horejs-Hoeck J., Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005, 18:243-249.
113. Kunisada K., Hirota H., Fujio Y., Matsui H., Tani Y., Yamauchi-Takihara K., et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 1996, 94:2626-2632.
114. Pelletier S., Duhamel F., Coulombe P., Popoff M.R., Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol Cell Biol 2003, 23:1316-1333.
115. Beckles D.L., Mascareno E., Siddiqui M.A.Q. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vasc Pharmacol 2006, 45:350-357.
116. Sano M., Abdellatif M., Oh H., Xie M., Bagella L., Giordano A., et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 2002, 8:1310-1317.
117. Sano M., Schneider M.D. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res 2004, 95:867-876.
118. Espinoza-Derout J., Wagner M., Shahmiri K., Mascareno E., Chaqour B., Siddiqui M.A.Q. Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res 2007, 75:129-138.
119. Liu J., Shen Q., Wu Y. Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sci 2008, 82:991-996.
120. Wang T.L., Yang Y.H., Chang H., Hung C.R. Angiotensin II signals mechanical stretch induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 2004, 37:785-794.
121. Sugden P.H., Clerk A. Activation of the small GTP-binding protein Ras in the heart by hypertrophic agonists. Trends Cardiovasc Med 2000, 10:1-8.
122. Ichida M., Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem 2001, 276:3524-3530.
123. Wu G., Yussman M.G., Barrett T.J., Hahn H.S., Osinska H., Hilliard G.M., et al. Increased myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy. Circ Res 2001, 89:1130-1137.
124. Filipeanu C.M., Zhou F., Wu G. Analysis of Rab1 function in cardiomyocyte growth. Methods Enzymol 2008, 438:217-226.
125. Lezoualc'h F., Métrich M., Hmitou I., Duquesnes N., Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 2008, 44:623-632.
126. Proud C.G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004, 63:403-413.
127. Ramirez M.T., Sah V.P., Zhao X.L., Hunter J.J., Chien K.R., Brown J.H. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem 1997, 272:14057-14061.
128. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004, 110:718-723.
129. Fuller S.J., Gillespie-Brown J., Sugden P.H. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem 1998, 273:18146-18152.
130. Charron F., Tsimiklis G., Arcand M., Robitaille L., Liang G., Molkentin J.D., et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 2001, 15:2702-2719.
131. Aikawa R., Komuro I., Yamazaki T., Zou Y., Kudoh S., Zhu W., et al. Rho family small G proteins play critical roles in mechanical stress induced hypertrophic responses in cardiac myocytes. Circ Res 1999, 84:458-466.
132. Torsoni A.S., Fonseca P.M., Crosara-Alberto D.P., Franchini K.G. Early activation of p160ROCK by pressure overload in rat heart. Am J Physiol Cell Physiol 2003, 284:C1411-C1419.
133. Kobayashi N., Horinaka S., Mita S., Nakano S., Honda T., Yoshida K., et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002, 55:757-767.
134. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004, 94:46-52.
135. Mita S., Kobayashi N., Yoshida K., Nakano S., Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in dahl salt-sensitive hypertensive rats. J Hypertens 2005, 23:87-96.
136. Zeidan A., Javadov S., Chakrabarti S., Karmazyn M. Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc Res 2008, 77:64-72.
137. Wang Y.X., da Cunha V., Martin-McNulty B., Vincelette J., Li W., Choy D.F., et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 2005, 512:215-222.
138. Hunter J.C., Zeidan A., Javadov S., Kilić A., Rajapurohitam V., Karmazyn M. Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. J Mol Cell Cardiol 2009, 47:810-818.
139. Ye Y., Hu S.J., Li L. Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway. FEBS Lett 2009, 583:2997-3003.
140. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
141. Pracyk J.B., Tanaka K., Hegland D.D., Kim K.S., Sethi R., Rovira I., et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest 1998, 102:929-937.
142. Sussman M.A., Welch S., Walker A., Klevitsky R., Hewett T.E., Price R.L., et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active Rac1. J Clin Invest 2000, 105:875-886.
143. Lu J.C., Cui W., Zhang H.L., Liu F., Han M., Liu D.M., et al. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2009, 36:1110-1119.
144. Azakie A., Fineman J.R., He Y. Myocardial transcription factors are modulated during pathologic cardiac hypertrophy in vivo. J Thorac Cardiovasc Surg 2006, 132:1262-1271.
145. Tshori S., Gilon D., Beeri R., Nechushtan H., Kaluzhny D., Pikarsky E., et al. Transcription factor MITF regulates cardiac growth and hypertrophy. J Clin Invest 2006, 116:2673-2681.
146. Wu S., Yin R., Ernest R., Li Y., Zhelyabovska O., Luo J., et al. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 2009, 84:119-126.
147. Farrance I.K., Ordahl C.P. The role of transcription enhancer factor-1 (TEF-1) related proteins in the formation of M-CAT binding complexes in muscle and non-muscle tissues. J Biol Chem 1996, 271:8266-8274.
148. Ueyama T., Zhu C., Valenzuela Y.M., Suzow J.G., Stewart A.F. Identification of the functional domain in the transcription factor RTEF-1 that mediates alpha 1-adrenergic signaling in hypertrophied cardiac myocytes. J Biol Chem 2000, 275:17476-17480.
149. Geng J., Zhao Z., Kang W., Wang W., Zhang Y., Zhiming G.E. Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats. Pharmacol Res 2010, 61:40-47.
150. Kimura T.E., Jin J., Zi M., Prehar S., Liu W., Oceandy D., et al. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 2010, 106:961-970.
151. Alvarez-Guardia D., Palomer X., Coll T., Davidson M.M., Chan T.O., Feldman A.M., et al. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res 2010, 87:449-458.
152. Hall G., Hasday J.D., Rogers T.B. Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol 2006, 41:580-591.
153. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., Lin A. Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 2001, 98:6668-6673.
154. Young D., Popovic Z.B., Jones W.K., Gupta S. Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice. J Mol Biol 2008, 381:559-568.
155. Li T., Wang Y., Liu C., Hu Y., Wu M., Li J., et al. MyD88-dependent nuclear factor-kappaB activation is involved in fibrinogen-induced hypertrophic response of cardiomyocytes. J Hypertens 2009, 27:1084-1093.
156. Mansky K.C., Sankar U., Han J., Ostrowski M.C. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 2002, 277:11077-11083.
157. Jenuwein T., Allis C. Translating the histone code. Science 2000, 293:1074-1080.
158. Fischle W., Wang Y., Allis C. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003, 15:172-183.
159. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
160. Lu Y., Yang S. Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases. Tohoku J Exp Med 2009, 219:17-23.
161. Kee H.J., Kook H. Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 2009, 47:770-780.
162. Zhang C.I. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
163. Soesanto W., Lin H.Y., Hu E., Lefler S., Litwin S.E., Sena S., et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 2009, 54:1321-1327.
164. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
165. Huss J.M., Kelly D.P. Nuclear receptor signaling and cardiac genetics. Circ Res 2004, 95:568-578.
166. Buse J.B. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003, 108:e57.
167. Balakumar P., Rose M., Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?. Pharmacology 2007, 80:1-10.
168. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol Res 2007, 56:91-98.
169. Rose M., Balakumar P., Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 2007, 80:177-184.
170. Young M.E., Laws F.A., Goodwin G.W., Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001, 276:44390-44395.
171. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801:311-319.
172. Ogata T., Miyauchi T., Sakai S., Irukayama-Tomobe Y., Goto K., Yamaguchi I. Stimulation of peroxisome proliferator activated receptor alpha (PPARα) attenuated cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002, 103:284S-288S.
173. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama-Tomobe Y., Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004, 43:1481-1488.
174. Balakumar P., Rose M., Singh M. Effect of fenofibrate in pressure overload-induced experimental cardiac hypertrophy. Int J Biol Chem 2007, 1:104-110.
175. De Silva D.S., Wilson R.M., Hutchinson C., Ip P.C., Garcia A.G., Lancel S., et al. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am J Physiol Heart Circ Physiol 2009, 296:H1983-H1993.
176. Meng R.S., Pei Z.H., Yin R., Zhang C.X., Chen B.L., Zhang Y., et al. Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-alpha signaling pathway. Eur J Pharmacol 2009, 620:63-70.
177. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
178. Diep Q.N., Benkirane K., Amiri F., Cohn J.S., Endemann D., Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004, 36:295-304.
179. Kobayashi N., Ohno T., Yoshida K., Fukushima H., Mamada Y., Nomura M., et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008, 21:576-581.
180. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., Glass C.K. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 2003, 100:6712-6717.
181. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
182. Smeets P.J., Teunissen B.E., Planavila A., de Vogel-van den Bosch H., Willemsen P.H., van der Vusse G.J., et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem 2008, 283:29109-29118.
183. Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The "suicide hypothesis" revisited. Trends Pharmacol Sci 2002, 23:122-129.
184. Oei S.L., Griesenbeck J., Schweiger M., Babich V., Kropotov A., Tomilin N. Interaction of the transcription factor YY1 with human poly (ADP-ribose) transferase. Biochem Biophys Res Commun 1997, 240:108-111.
185. Butler A.J., Ordahl C.P. Poly (ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle specific transcription. Mol Cell Biol 1999, 19:296-306.
186. Hassa P.O., Buerki C., Lombardi C., Imhof R., Hottiger M.O. Transcriptional coactivation of nuclear factor-kB-dependent gene expression by p300 is regulated by poly (ADP)-ribose polymerase-1. J Biol Chem 2003, 278:45145-45153.
187. Kraus W.L., Lis J.T. PARP goes transcription. Cell 2003, 113:677-683.
188. Pillai J.B., Russell H.M., Raman J.S., Jeevanandam V., Gupta M.P. Increased expression of poly (ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005, 288:H486-H496.
189. Virag L., Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54:375-429.
190. Balakumar P., Singh M. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp Clin Pharmacol 2006, 28:683-689.
191. Balakumar P., Singh M. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int J Pharmacol 2006, 2:543-548.
192. Bartha E., Kiss G.N., Kalman E., Kulcsár G., Kálai T., Hideg K., et al. Effect of L-2286, a poly(ADP-ribose) polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J Cardiovasc Pharmacol 2008, 52:253-261.
193. Bartha E., Solti I., Kereskai L., Lantos J., Plozer E., Magyar K., et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 2009, 83:501-510.
194. van Empel V.P., De Windt L.J. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 2004, 63:487-499.
195. Li Z., Bing O.H.L., Long X., Robinson K.G., Lakatta E.G. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 1997, 272:H2313-H2319.
196. van Empel V.P., Bertrand A.T., Hofstra L., Crijns H.J., Doevendans P.A., De Windt L.J. Myocyte apoptosis in heart failure. Cardiovasc Res 2005, 67:21-29.
197. Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000, 45:528-537.
198. Teiger E., Dam T.V., Richard L., Wisnewsky C., Tea B.S., Gaboury L., et al. Apoptosis in pressure overload induced heart hypertrophy in the rat. J Clin Invest 1996, 97:2891-2897.
199. Philipp S., Pagel I., Hohnel K., Lutz J., Buttgereit J., Langenickel T., et al. Regulation of caspase 3 and Fas in pressure overload-induced left ventricular dysfunction. Eur J Heart Fail 2004, 6:845-851.
200. Communal C., Sumandea M., deTombe P., Narula J., Solaro R.J., Hajjar R.J. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002, 99:6252-6256.
201. Balsam L.B., Kofidis T., Robbins R.C. Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction. J Surg Res 2005, 124:194-200.
202. Choi Y.H., Cowan D.B., Moran A.M., Colan S.D., Stamm C., Takeuchi K., et al. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 2009, 137:1356-1362.
203. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
204. Balakumar P., Reddy J., Singh M. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?. Mol Cell Biochem 2009, 330:187-192.
205. Balakumar P., Singh A.P., Ganti S.S., Krishan P., Ramasamy S., Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy?. Basic Clin Pharmacol Toxicol 2008, 102:5-9.
206. Singh A.P., Singh M., Balakumar P. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol 2008, 51:596-604.
207. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010, 23:192-196.
208. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008, 283:24194-24201.
209. Olson E., Naugle J., Zhang X., Bomser J., Meszaros J. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 2005, 288:H1131-H1138.
210. Aubin M., Lajoie C., Clément R., Gosselin H., Calderone A., Perrault L. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008, 210(325):961-968.
211. Sutra T., Oiry C., Azay-Milhau J., Youl E., Magous R., Teissèdre P., et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem 2008, 56:11683-11687.
212. Shen D.F., Tang Q.Z., Yan L., Zhang Y., Zhu L.H., Wang L., et al. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol 2010, 159:970-981.
213. Wang M., Zhang J., Walker S.J., Dworakowski R., Lakatta E.G., Shah A.M. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 2010, 48:765-772.
214. Cai J., Yi F.F., Bian Z.Y., Shen D.F., Yang L., Yan L., et al. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 2009, 13:909-925.
215. Mao Z., Liang Y., Du X., Sun Z. 3,3',4',5,7-Pentamethylquercetin reduces angiotensin II-induced cardiac hypertrophy and apoptosis in rats. Can J Physiol Pharmacol 2009, 87:720-728.
216. Ikeda Y., Sato K., Pimental D.R., Sam F., Shaw R.J., Dyck J.R., et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem 2009, 284:35839-35849.
217. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMPK pathway. J Biol Chem 2010, 285:3133-3144.
218. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 2009, 119:2758-2771.
219. Ardanaz N., Yang X.P., Cifuentes M.E., Haurani M.J., Jackson K.W., Liao T.D., et al. Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension. Hypertension 2010, 55:116-123.
220. Zhu W., Trivedi C.M., Zhou D., Yuan L., Lu M.M., Epstein J.A. Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res 2009, 105:1240-1247.
221. Mustonen E., Pohjolainen V., Aro J., Pikkarainen S., Leskinen H., Ruskoaho H., et al. Upregulation of cardiac matrix Gla protein expression in response to hypertrophic stimuli. Blood Press 2009, 18:286-293.
222. Katsuragi N., Morishita R., Nakamura N., Ochiai T., Taniyama Y., Hasegawa Y., et al. Periostin as a novel factor responsible for ventricular dilation. Circulation 2004, 110:1806-1813.
223. Stansfield W.E., Andersen N.M., Tang R.H., Selzman C.H. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg 2009, 88:1916-1921.
224. Connelly K.A., Kelly D.J., Zhang Y., Prior D.L., Advani A., Cox A.J., et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009, 2:129-137.
225. Borrás C., Gambini J., López-Grueso R., Pallardó F.V., Viña J. Direct antioxidant and protective effect of estradiol on isolated mitochondria. Biochim Biophys Acta 2010, 1802:205-211.
226. Gardner J.D., Murray D.B., Voloshenyuk T.G., Brower G.L., Bradley J.M., Janicki J.S. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 2009, 298:H497-504.
227. Bhuiyan M.S., Fukunaga K. Stimulation of Sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats. Expert Opin Ther Targets 2009, 13:1253-1265.
228. Lowe M.C., Reichenbach D.D., Horita A. Extraneuronal monoamine oxidase in rat heart: biochemical characterization and electron microscopic localization. J Pharmacol Exp Ther 1975, 194:522-536.
229. Rodriguez M.J., Saura J., Billett E.E., Finch C.C., Mahy N. Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res 2001, 304:215-220.
230. Kaludercic N., Takimoto E., Nagayama T., Feng N., Lai E.W., Bedja D., et al. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 2010, 106:193-202.
231. Okin P.M., Devereux R.B., Kligfield P. Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. Hypertension 1996, 28:3-7.
232. Lazaro A., Alvarez-Llamas G., Gallego-Delgado J., de la Cuesta F., Osende J., Barderas M.E.G., et al. Pharmacoproteomics in cardiac hypertrophy and atherosclerosis. Cardiovasc Haematol Disorders Drug Targets 2009, 9:141-148.
233. Liao Y., Zhao H., Ogai A., Kato H., Asakura M., Kim J., et al. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008, 31:335-344.
234. Planavila A., Rodríguez-Calvo R., Palomer X., Coll T., Sánchez R.M., Merlos M., et al. Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli. Biochim Biophys Acta 2008, 1781:26-35.
235. Kang B.Y., Mehta J.L. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther 2009, 14:283-291.
236. Kang B.Y., Wang W., Palade P., Sharma S.G., Mehta J.L. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 2009, 54:327-334.
237. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105:868-873.
238. Osorio J.C., Cheema F.H., Martens T.P., Mahmut N., Kinnear C., Gonzalez A.M., et al. Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol 2008, 86:633-642.
239. Louhelainen M., Merasto S., Finckenberg P., Vahtola E., Kaheinen P., Leskinen H., et al. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. J Physiol Pharmacol 2009, 60:41-47.
240. Harzheim D., Talasila A., Movassagh M., Foo R.S., Figg N., Bootman M.D., et al. Elevated InsP3R expression underlies enhanced calcium fluxes and spontaneous extra-systolic calcium release events in hypertrophic cardiac myocytes. Channels (Austin) 2010, 4:67-71.
241. Lai Z.F. TNNI3K could be a novel molecular target for the treatment of cardiac diseases. Recent Pat Cardiovasc Drug Discov 2009, 4:203-210.
242. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251:471-476.
243. Kleinz M.J., Skepper J.N., Davenport A.P. Immunocytochemical localization of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005, 126:233-240.
244. Maguire J.J., Kleinz M.J., Pitkin S.L., Davenport A.P. [Pyr1] apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009, 54:598-604.
245. Cheng X., Cheng X.S., Pang C.C. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003, 470:171-175.
246. Kagiyama S., Fukuhara M., Matsumura K., Lin Y., Fujii K., Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005, 125:55-59.
247. Foldes G., Horkay F., Szokodi I., Vuolteenaho O., Ilves M., Lindstedt K.A., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003, 308:480-485.
248. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006, 8:355-360.
249. Weir R.A., Chong K.S., Dalzell J.R., Petrie C.J., Murphy C.A., Steedman T., et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 2009, 11:551-558.
250. Kuba K., Zhang L., Imai Y., Arab S., Chen M., Maekawa Y., et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007, 101:e32-42.
251. Quazi R., Palaniswamy C., Frishman W.H. The emerging role of apelin in cardiovascular disease and health. Cardiol Rev 2009, 17:283-286.
252. Iwanaga Y., Kihara Y., Takenaka H., Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006, 41:798-806.
253. Fukushima H., Kobayashi N., Takeshima H., Koguchi W., Ishimitsu T. Effects of olmesartan on apelin/APJ and Akt/eNOS pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 2010, 55:83-88.
254. Falcão-Pires I., Gonçalves N., Henriques-Coelho T., Moreira-Gonçalves D., Roncon-Albuquerque R., Leite-Moreira A.F. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009, 296:H2007-H2014.
255. Falcão-Pires I., Gonçalves N., Gavina C., Pinho S., Teixeira T., Moura C., et al. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment?. Expert Opin Ther Targets 2010, 14:231-241.
256. Kaye D.M., Krum H. Drug discovery for heart failure: a new era or the end of the pipeline?. Nat Rev Drug Discov 2007, 6:127-139.
257. Rajagopal K., Whalen E.J., Violin J.D., Stiber J.A., Rosenberg P.B., Premont R.T., et al. β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006, 103:16284-16289.
258. Patel P.A., Tilley D.G., Rockman H.A. Beta-arrestin-mediated signaling in the heart. Circ J 2008, 72:1725-1729.
259. Rosenkranz A.C., Woods R.L., Dusting G.J., Ritchie R.H. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003, 57:515-522.
260. Fiedler B., Lohmann S.M., Smolenski A., Linnemuller S., Pieske B., Schroder F., et al. Inhibition of calcineurin-NFAT signaling by cGMP dependent protein kinase type 1 in cardiac myocytes. Proc Natl Acad Sci USA 2002, 99:11363-11368.
261. Wang D., Oparil S., Feng J.A., Li P., Perry G., Chen L.B., et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 2003, 42:88-95.
262. He J.G., Chen Y.L., Chen B.L., Huang Y.Y., Yao F.J., Chen S.L., et al. B-type natriuretic peptide attenuates cardiac hypertrophy via TGF-beta1/smad7 pathway in vivo and in vitro. Clin Exp Pharmacol Physiol 2010, 37:283-289.
263. Hsu S., Nagayama T., Koitabashi N., Zhang M., Zhou L., Bedja D., et al. Phosphodiesterase-5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009, 81:301-309.
264. Li L., Chen G.P., Yang Y., Ye Y., Yao L., Hu S.J. Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol 2010, 79:399-406.
265. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol 2009, 47:835-845.
266. Jaski B.E., Jessup M.L., Mancini D.M., Cappola T.P., Pauly D.F., Greenberg B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009, 15:171-181.
267. Micheletti R., Palazzo F., Barassi P., Giacalone G., Ferrandi M., Schiavone A., et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 2007, 99:24A-32A.
268. Shah S.J., Blair J.E., Filippatos G.S., Macarie C., Ruzyllo W., Korewicki J., et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J 2009, 157:1035-1041.
269. Chiu C.Z., Wang B.W., Chung T.H., Shyu K.G. Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes. Clin Sci (Lond) 2010, 119:273-282.
270. George I., Bish L.T., Kamalakkannan G., Petrilli C.M., Oz M.C., Naka Y., et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 2010, 12:444-453.
271. Wang B.W., Chang H., Kuan P., Shyu K.G. Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway. J Endocrinol 2008, 197:85-93.
272. Nakamoto M., Ohya Y., Shinzato T., Mano R., Yamazato M., Sakima A., et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens Res 2008, 31:353-361.
273. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y.F., et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008, 51:296-301.
274. Wenzel S., Taimor G., Piper H.M., Schlüter K.D. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation. AP-1 binding activity, and TGF-β expression in adult ventricular cardiomyocytes. FASEB J 2001, 15:2291-2293.
275. 1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002, 109:787-796.
276. Hao J., Wang B., Jones S.C., Jassal D.S., Dixon I.M.C. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000, 279:H3020-H3030.
277. Dixon I.M., Hao J., Reid N.L., Roth J.C. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000, 46:286-297.
278. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000, 6:556-563.
279. Massague J. TGF-β signaling: receptors, transducers, and mad proteins. Cell 1996, 85:947-950.
280. Moustakas A., Souchelnytskyi S., Heldin C.-H. Smad regulation in TGF-β signal transduction. J Cell Sci 2001, 114:4359-4369.
281. Monzen K., Shiojima I., Hiroi Y., Kudoh S., Oka T., Takimoto E., et al. Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol 1999, 19:7096-7105.
282. Monzen K., Hiroi Y., Kudoh S., Akazawa H., Oka T., Takimoto E., et al. Smads, TAK1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. J Cell Biol 2001, 153:687-698.
283. Miao C.Y., Xie H.H., Wang J.J., Su D.F. Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002, 23:713-720.
284. Iwashima Y., Okada M., Haneda M., Yoshida T. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan. Diabetes Res Clin Pract 2006, 74:8-14.
285. Yasunari K., Maeda K., Watanabe T., Nakamura M., Yoshikawa J., Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004, 43:2116-2123.
286. Kassab S., Garadah T., Abu-Hijleh M., Golbahar J., Senok S., Wazir J., et al. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J Renin Angiotensin Aldosterone Syst 2006, 7:206-211.
287. Zhou N., Li L., Wu J., Sun A., Ge J., Zou Y. Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. Biochem Biophys Res Commun 2010, 397:263-269.
288. Ichihara S., Senbonmatsu T., Price E., Ichiki T., Gaffney F.A., Inagami T. Angiotensin type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001, 104:346-351.
289. Jones E.S., Black M.J., Widdop R.E. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004, 37:1023-1030.
290. Brower G.L., Levick S.P., Janicki J.S. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 2007, 292:H3057-H3064.
291. Bohm M., Kouchi I., Schnabel P., Zolk O. Transition from hypertrophy to failure-β-adrenergic desensitization of the heart. Heart Fail Rev 1999, 4:329-351.
292. Schluter K.-D., Zhou X.J., Piper H.M. Induction of hypertrophic responsiveness to isoproterenol by TGF-β in adult rat cardiomyocytes. Am J Physiol 1995, 269:C1311-C1316.
293. 1. Am J Physiol Heart Circ Physiol 2002, 283:H1253-H1262.
294. Machackova J., Sanganalmath S.K., Barta J., Dhalla K.S., Dhalla N.S. Amelioration of cardiac remodeling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol 2010, 10:9-16.
295. Chua S., Sheu J.J., Chang L.T., Lee F.Y., Wu C.J., Sun C.K., et al. Comparison of losartan and carvedilol on attenuating inflammatory and oxidative response and preserving energy transcription factors and left ventricular function in dilated cardiomyopathy rats. Int Heart J 2008, 49:605-619.
296. Barone F.C., Willette R.N., Nelson A.H., Ohlstein E.H., Brooks D.P., Coatney R.W. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. Pharmacology 2007, 80:166-176.
297. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007, 104:16657-16662.
298. Hanada K., Asari K., Saito M., Kawana J., Mita M., Ogata H. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. Eur J Pharmacol 2008, 589:194-200.
299. Xiaozhen H., Yun Z., Mei Z., Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press 2010, 19:40-47.
300. Noma T., Lemaire A., Naga Prasad S.V., Barki-Harrington L., Tilley D.G., Chen J., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007, 117:2445-2458.
301. Manhiani M., Quigley J.E., Knight S.F., Tasoobshirazi S., Moore T., Brands M.W., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 2009, 297:F740-F748.
302. Balakumar P., Jagadeesh G. Cardiovascular and renal pathological implications of prorenin, renin and (pro)renin receptors: promising young players from the old RAAS. J Cardiovasc Pharmacol 2010, 10.1097/FJC.0b013e3181f21576.